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Background: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor
(TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered,
little data exist regarding Asian patient populations.
Methods: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later
acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and
after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET
amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal
transition (EMT) and neuroendocrine markers by immunohistochemistry.
Results: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR
mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation
was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased
AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one
patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform
(PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine
differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred
in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M
mutation showed a more favorable prognosis.
Conclusion: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those
observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance
are necessary.
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Lung cancer is the leading cause of cancer deaths [1].
Three out of four patients present with advanced-stage
disease, and the prognosis is generally poor. However,
recent advances with targeted therapies, such as epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs), have resulted in marked benefit to subsets of lung
cancer patients whose tumors have specific genetic muta-
tions. However, despite the initial beneficial effect of
EGFR-TKI treatment, most patients with non-small cell
lung cancer (NSCLC) eventually develop resistance to
EGFR-TKIs, with a median time to disease progression of
about 12 months [2,3]. Secondary biopsy of growing tu-
mors at the onset of clinical progression is crucial for
identifying the mechanisms of resistance, although this is
often not easily accomplished.
Recent efforts to develop strategies for overcoming ac-
quired resistance to EGFR-TKIs have identified severalre-
sistance mechanisms. Approximately half of the cases of
acquired resistance are mediated by a secondary T790M
mutation on exon 20 of the EGFR gene [4-6]. In addition,
amplification of the MET gene has been reported to con-
tribute to resistance in approximately 5–20% of cases [6-8]
and increased AXL expression was recently discovered to
occur in almost 20% of patients [9] phosphatidylinositol-4,
5-bisphosphate 3-kinase catalytic subunit alpha isoform
(PIK3CA) mutation, epithelial-to-mesenchymal transition
(EMT) and small cell lung cancer (SCLC) transformation
are also associated with acquired resistance [6]. Although
some studies have examined the mechanisms and fre-
quency of EGFR-TKI resistance, little data exists regarding
Asian populations of cancer patients. The aim of this study
was to analyze the mechanisms of acquired resistance to




We reviewed the medical records of patients with NSCLC
with EGFR mutations and acquired resistance to EGFR-
TKI between 2007 and 2010. All patients fulfilled the def-
inition of acquired resistance to EGFR-TKI [10], which
was defined as having received treatment with a single
agent EGFR-TKI, exhibiting objective clinical benefit from
treatment, and then experiencing disease progression
while under continuous treatment with EGFR-TKI. At the
time drug resistance developed, some patients underwent
post-resistance biopsy for evaluation of the mechanisms of
resistance. We selected patients from whom the tissues
obtained both before EGFR-TKI treatment and after re-
sistance were sufficient to assess EGFR, KRAS, BRAF, and
PIK3CA mutations by “Asan-Panel” analysis, perform
fluorescence in situ hybridization (FISH) to identify
MET amplification, and examine AXL status, EMT andneuroendocrine markers by immunohistochemistry. All
patients provided informed consent, and the study was
approved by the Institutional Review Board of the
Asan Medical Center (Approval Number: 2011–0526).
Mutation analysis
A mass spectrometric genotyping technology, called the
“Asan-Panel”, was used for genetic analysis. First, DNA was
extracted from paraffin-embedded tissues using QIAamp
DNA FFPE tissue kit (#56404; Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. DNA quantity
was measured using the Quant-iT™ PicoGreen® dsDNA
Assay kit (Invitrogen, Carlsbad, CA) andbrought to a final
concentration of 5 ng/μl. Mutation analysis using the
Asan-Panel was performed under the SequenomMassAR-
RAY technology platform with iPLEX-Pro chemistry
(Sequenom, San Diego, USA). The protocols that were
previously performed as “OncoMap” [11-13] were followed
with minor modifications. In brief, specific assay pools
were designed using AssayDesignersoftware in MassAR-
RAY Typerpackage software (v4.0) with filters for proximal
single nucleotide polymorphisms (SNPs) and assessment of
the specificity of PCR amplification and the subsequent
primer extension reaction. To decrease the number of
multiplex PCR tubes, manual modification of some PCR
primers and extension probes was conducted. A total of 59
amplicons were amplified in eight different multiplex pools
with an average of 8-plex. After multiplex PCR, residual
deoxynucleotides were inactivated by incubation with
Shrimp Alkaline Phosphatase (Catalog No. 10142–2,
Sequenom). Single-base extension (SBE) reaction prod-
ucts using a mixture of mutation site-specific probes
were then spotted onto a 384-format SpectroCHIP II
with the MassARRAY Nanodispenser. Mass determin-
ation was performed with the MassARRAY Analyzer
Compact MALDI-TOF mass spectrometer, and Mas-
sARRAY Typer 4.0 software was used for data acquisi-
tion and analysis. Genotypes were called after cluster
analysis using the default setting of the Gaussian mix-
ture model. Genotype calls were then reviewed manu-
ally to identify any uncertain calls due to clustering
artifacts. A total of 87 genetic mutations located in
EGFR, KRAS, BRAF and PIK3CA genes were examined
by Asan-Panel analysis.
FISH analysis for MET amplification
For FISH, 2 μm-thick sections from each paraffin block
were prepared. Deparaffinization, pre-treatment and pro-
tease digestion procedures were performed following the
Abbott Vysis D7S522/CEP 7 FISH probe kit protocol
(Abbott Laboratories, Abbott Park, Des Plaines, IL,
USA). Probe mixtures were hybridized at 37°C for 14
to 18 hours. After hybridization, slides were washed in
2× SSC/0.3% NP-40 at 72°C for 2 min, air dried, and
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The slides were examined under a fluorescence microscope
(Olympus, Tokyo, Japan) equipped with Spectrum Orange/
Green dual and DAPI single filters. The slides were stored
at −20°C until examination. A c-met/CEP7 ratio was estab-
lished on the basis of a count of at least 60 cells by enu-
merating both orange (c-met) and green (chromosome 7,
CEP7) signals. Samples with a c-met/CEP7 ratio greater
than 2 were considered to have MET amplification.
Immunohistochemistry for AXL, EMT and neuroendocrine
markers
All biopsy specimens underwent histologic review after
H&E and immunohistochemical staining for specific
markers, such as thyroid transcription factor 1 (TTF-1).
For immunohistochemical analysis, paraffin sections
(4 μm thick) were deparaffinized with xylene, rinsed
thoroughly with ethanol, and then soaked in 0.03%
hydrogen peroxide in methanol to inactivate the en-
dogenous peroxidase activity. The sections were incu-
bated with either 10% goat serum or 10% rabbit serum,
and then incubated with the primary antibodies. The sec-
tions were washed with phosphate-buffered saline (PBS)
and processed using a DAKO EnVision kit (DAKO, Los
Angeles, CA), as directed by the manufacturer. The color
was developed with 3,3′-diaminobenzindine (DAB) con-
taining 0.3% H2O2. Primary antibodies against the following
antigens were used: CD56, synaptophysin and chromogra-
nin (Santa Cruz Biotechnology, Santa Cruz, CA) for SCLC
transformation; E-cadherin and vimentin (Calbiochem, San
Diego, CA) for EMT; AXL and p-AXL (R&D Systems,
Minneapolis, MN) for AXL status.
Results
Baseline clinical and molecular characteristics
Twenty-six patients were eligible for this study; of these,
10 patients (38.5%) were male and 16 (61.5%) were fe-
male. The median age was 58-years-old. All patients ex-
cept one were diagnosed with adenocarcinoma of the
lung with EGFR mutation at initial diagnosis. One pa-
tient had squamous cell carcinoma with a deletion mu-
tation on exon 19 of EGFR. The deletion mutation on
exon 19 of EGFR gene was present in 16 patients
(61.5%), while the L858R point mutation on exon 21
was noted in 10 (38.5%). All patients were treated with
gefitinib and showed a partial response. The secondary
biopsy sites were lung (65.4%), mediastinal or cervical
lymph nodes (19.2%), liver (7.7%), malignant pleural effu-
sion (3.8%), and bone (3.8%). The biopsy site after resist-
ance was same as the initial site in 15 patients (Table 1).
Resistance mechanisms to EGFR-TKI
Secondary T790M mutation was detected in 11 patients
(42.3%), four of which had additional resistance mechanisms:MET amplification was observed in two patients, increased
AXL expression in one patient, and PIK3CA mutation in
one patient. Increased AXL expression (Figure 1) was seen
in 5/26 patients (19.2%), while MET gene amplification was
noted in 3/26 patients (11.5%). One patient acquired an
H1047L point mutation in the PIK3CA gene, which was ac-
companied by the T790M mutation. No patient exhibited
evidence of EMT, whereas increased CD56 expression sug-
gesting neuroendocrine differentiationwas observed in two
patients. However, the morphologic change and expression
of synaptophysin and chromogranin was not evident in these
patients (Figure 2). Interestingly, conversion from L858R-
mutant to wild-type EGFR occurred in one patient (Figure 3).
Seven of the patients (26.9%) did not exhibit any known
EGFR-TKI resistance mechanisms. The frequency of resist-
ance mechanisms is shown in Figure 4.
Outcomes
Median progression-free survival (PFS) following gefi-
tinib treatment was 11 months, and the median overall
survival (OS) time was 32.3 months. PFS was significantly
better in patients with secondary T790M mutation than in
those without T790M (p = 0.009, Figure 5), while OS was
not statistically different (p = 0.617, Figure 5).
Discussion
In this study, we explored themechanisms of resistance
to EGFR-TKI and their frequency in a Korean popula-
tion. Because biopsy after disease progression following
EGFR-TKI treatment is often challenging, few studies re-
garding the onset of EGFR-TKI resistance exist, and this
is especially true of EGFR-TKI resistance in Asian popu-
lations, even though EGFR mutations in Asian patients
are frequent.
Similar to the data published in previous reports
[6,14], we observed that secondary T790M mutation
was the most common mechanism of EGFR-TKI resist-
ance, representing 43.9% of all cases. The sensitivity of
mass spectrometric genotyping technologies such as
OncoMap or Asan-Panel is known to be approximately
1–5% [6,15], and so detection of the T790M mutation
could be increased if more sensitive techniqueswere
used. Interestingly, four patients with T790M had co-
existing resistance mechanisms such as MET amplifica-
tion, increased AXL expression and PIK3CA mutation.
Simultaneous occurrence of two resistant mechanisms
has been reported by several investigators. For ex-
ample, Sequist LV et al. showed that some patients
with a T790M mutation exhibited other possible con-
tributing factors to resistance, such as EGFR amplifica-
tion or β-catenin and APC mutation [6]. In addition,
among 10 EGFR-TKI-resistant tumors from nine pa-
tients with MET amplification, four also expressed
EGFR with the T790M mutation [8]. Supporting this,
Table 1 Baseline characteristics, clinical course and mechanism of acquired resistance to EGFR-TKI in 26 patients
SN Sex Age Histology EGFR mutation Changes in 2nd Bx TKI PFS (months) OS (months) Bx site
1st 2nd
1 M 80 ACC 19 del T790M + H1047L (PIK3CA) Gefitinib 34.7 65.7 RUL RUL
2 F 40 ACC 19 del T790M Gefitinib 12.7 17.1 LLL LN
3 F 48 ACC L858R T790M + AXL Gefitinib 11.5 38.9 LLL RLL
4 F 64 SqCC 19 del T790M +MET amp Gefitinib 7.8 14.2 RUL RUL
5 F 73 ACC L858R T790M +MET amp Gefitinib 13.1 47.7 RLL RLL
6 M 67 ACC L858R T790M Gefitinib 16.7 29.1 RUL Liver
7 M 53 ACC 19 del T790M Gefitinib 15.8 79.4 LUL LUL
8 F 48 ACC 19 del T790M Gefitinib 18.9 50.9 LN LN
9 F 57 ACC 19 del T790M Gefitinib 16.2 37.2 LLL Effusion
10 M 56 ACC 19 del T790M Gefitinib 14.8 28.9 RUL RUL
11 F 54 ACC 19 del T790M Gefitinib 28.7 58.2 RML LN
12 M 49 ACC L858R WT EGFR Gefitinib 6.6 89.2 RUL Liver
13 F 50 ACC 19 del MET amp Gefitinib 10.7 35.2 LN LUL
14 F 64 ACC L858R AXL Gefitinib 25.4 94.6 LUL RUL
15 M 67 ACC 19 del AXL Gefitinib 11.4 30.2 LUL Bone
16 M 59 ACC 19 del AXL Gefitinib 4.3 41.3 RLL LN
17 F 76 ACC 19 del AXL Gefitinib 10.7 31.0 RUL RUL
18 F 72 ACC 19 del None Gefitinib 26.1 46.4 RML RML
19 F 51 ACC L858R None Gefitinib 6.1 23.0 Bone LN
20 M 63 ACC L858R None Gefitinib 5.0 9.6 RLL RLL
21 F 73 ACC L858R None Gefitinib 3.9 25.1 LN LN
22 F 66 ACC L858R None Gefitinib 4.8 21.2 LUL LUL
23 F 57 ACC 19 del None Gefitinib 11.0 36.2 LUL LUL
24 M 65 ACC L858R None Gefitinib 5.4 20.6 RLL RLL
25 F 56 ACC 19 del CD56↑ Gefitinib 8.7 32.3 RUL RUL
26 M 50 ACC 19 del CD56↑ Gefitinib 5.9 15.4 LUL LUL
ACC, Adenocarcinoma; SqCC, Squamous cell carcinoma; TKI, Tyrosine kinase inhibitor; PFS, Progression-free survival; OS, Overall survival; Bx, Biopsy; RUL, Right
upper lobe; RML, Right middle lobe; RLL, Right lower lobe; LUL, Left upper lobe; LLL, Left lower lobe; LN, Lymph node; WT, Wild-type; ↑, increased expression.
Figure 1 Representative photomicrographs of AXL immunohistochemical staining. (A) The original tumor cells before EGFR-TKI treatment
were negative for AXL in immunohistochemical staining. (B) Tumor cells resistant to EGFR-TKI were immuno-positive for AXL.
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Figure 2 Increased CD56 expression in two patients. (A) The initial biopsy showed typical adenocarcinoma in H&E staining. (B) There were
no significant morphological changes of tumor cells with persistent immuno-positivity for TTF-1 after resistance. (C) The expression of CD56 was
negative in initial sample. (D) CD56 expression in some cells of tissues obtained after resistance was increased.
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and resistant (T790M) EGFR mutations also contains
MET amplification and is more sensitive to MET in-
hibition than EGFR inhibition [8]. Secondary T790M
mutation seems to be acquired by the selection of pre-
existing populations of T790M-harboring cells among
the total tumor cells during the period of treatment
with EGFR-TKI [16,17]. During this time, tumor cells
possessing a resistance mechanism in addition to
T790M could be more favorably selected.Figure 3 Histomorphological changesin tumor cells after conversion
when they harbored the L858R EGFR mutation. (B) Tumor cells were clus
EGFR-expressing cells. These tumor cells strongly expressed TTF-1, confirOxnard GR et al. reported that patients with tumors
harboring T790M mutation had more favorable out-
comes, and that those without T790M more frequently
progress to previously uninvolved organs. They sug-
gested that the favorable outcome could be related
tothe indolent growth of tumors containing the
T790M mutation [18]. In agreement with these find-
ings, we also observed that patients with secondary
T790M mutation showed significantly longer progression-
free survival (p = 0.009).to wild-type EGFR. (A) Tumor cells formed a glandular configuration
tered in a compact solid pattern after they converted to wild-type
ming that it is still adenocarcinoma.
Figure 4 The frequency of acquired EGFR-TKI resistance in 26
patients. Secondary T790M mutation was the most common
mechanism, found in 11 patients (42.3%). Four patients had other
co-existing resistant mechanisms (MET:2, AXL:1, PI3KCA:1). Increased AXL
expression was observed in 5/26 patients (19.2%), while MET gene
amplification was noted in 3/26 patients (11.5%). One patient acquired
a mutation in the PIK3CA gene and 2 patients showed increased CD56
expression, suggesting neuroendocrine differentiation. Conversion
from L858R-mutant to wild-type EGFR-expressing cells occurred in
1 patient, and 7 patients (26.9%) did not exhibit any known
resistance mechanisms.
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sion could contribute to erlotinib-resistance in both cell
lines and an animal model. Altered AXL-related signal-
ing was also observed in approximately 20% of patients
with acquired resistance to EGFR-TKI, although it re-
mains to be determined whether these patients could
benefit from AXL inhibition [9]. In EGFR-TKI resist-
ance, AXL could act as a bypass to activate downstreamFigure 5 Progression-free survival (PFS) and overall survival (OS) acco
patients with secondary T790M mutation than in those without T790M (15
different (38.9 months vs 38.9 months, p = 0.617).signals related to cell survival and growth. Therefore,
combined treatment with EGFR and AXL inhibitors
might effectively abrogate the growth of tumor cells. A
similar phenomenon can be observed in MET-mediated
resistance, as shown in a previous report by Engelman
JA et al. [7]. Although the frequency of MET amplifica-
tion in cases of EGFR-TKI resistance was initially re-
ported to be 20% [7], this has varied by approximately
5–11% in follow-up studies [6,14,19]. Similarly, the exact
frequency of AXL-mediated resistance should be deter-
mined by further investigation.
Sequist LV et al. found that 14% of biopsy specimens
taken at the onset of resistance showed morphologies
similar to SCLC, as well as increased expression of neu-
roendocrine markers such as CD56, synaptophysin and
chromogranin. In their study, three patients treated with
conventional chemotherapeutic agents for SCLC, includ-
ing etoposide and cisplatin, responded well [6]. In an-
other study, biopsy after the onset of resistance showed
that approximately 3% of NSCLC tumors exhibited mor-
phological transformation to small cell or high grade
neuroendocrine carcinomas [14]. These findings suggest
that transformation to SCLC or neuroendocrine carcin-
oma could be a possible mechanism of resistance. Al-
though pulmonary alveolar cells have been found to
transform occasionally to a small cell morphology
when loss of p53 and Rb1 is induced [20], the bio-
logical underpinning of the SCLC transformation is
unknown. In our study, we observed increased CD56
expression in 7.7% of patients. However, because it was
not accompanied by the morphologic change and up-
regulation of other neuroendocrinemarkers, such as
synaptophysin and chromogranin, the reason for this is
not clear.
Other possible resistance mechanisms, specifically PIK3CA
mutation and conversion to wild-type EGFR were noted in
some cases, although PIK3CA mutation concomitantly oc-
curred with T790M mutation. In a previous in vitro study,
gefitinib-induced apoptosis was abrogated when PIK3CArding to the T790M mutation. PFS was significantly better in
.8 months vs 6.6 months, p = 0.009), while OS was not statistically
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mutation in exon 19 of the EGFR gene [21]. Moreover,
Sequist LV et al. reported cases of EGFR-TKI resistance in
tumors with a PIK3CA mutation [6]. Thus, although
PIK3CA mutation may be a contributing factor to EGFR-
TKI resistance, it is not frequent. Some studies have
reportedthe loss of EGFR-activating gene mutations in re-
sistant tumor samples [22,23]. This could happen through
the selection of pre-existing tumor cells expressing
wild-type EGFR during EGFR-TKI treatment, similar
to the effect of the T790M mutation. However, because
EGFR mutation is considered to be a driver mutation
for carcinogenesis, the presence of another driving fac-
tor to induce tumor cells with wild-type EGFR would
be necessary, suggesting that this event would be very
rare.
As the data about resistant mechanisms have been ac-
cumulated, the procurement of resistant samples to
guide following treatments is becoming more important.
However, the performing the re-biopsy is not so easy in
clinical practice. Attempts to use circulating tumor cells
or circulating free DNAs in bloods or other body fluids
(“so-called liquid biopsy”) are currently in progress be-
cause those are non-invasive, convenient and can be per-
formed repeatedly [24,25]. Technical advances in tests
and processing samples would help this liquid biopsy to
have broad clinical applications, especially in elucidation
of resistant mechanisms.Conclusions
Our study is the first to present data regarding EGFR-TKI
resistance mechanisms and their frequency in a Korean
population. The mechanisms and frequency of acquired
EGFR-TKI resistance in Koreans are comparable to those
observed in Western populations. However, this study is
limited by the small number of patients. In addition, it is a
single center study that utilized retrospective analysis,
making generalization of the results difficult. Therefore, a
greater effort to procure appropriate tissues in instances
of acquired EGFR-TKI resistance will be necessary for the
results presented here to be confirmed by more extensive
studies. Although secondary biopsy is difficult at the time
of disease progression and the exact timing for secondary
biopsy should be determined, these efforts will provide the
data necessary to develop strategies for overcoming
EGFR-TKI resistance, leading to a better prognosis for pa-
tients with lung cancer.
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